Stock Analysis
Karolinska Development Second Quarter 2024 Earnings: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023)
Karolinska Development (STO:KDEV) Second Quarter 2024 Results
Key Financial Results
- Net loss: kr16.0m (down by 169% from kr23.3m profit in 2Q 2023).
- kr0.059 loss per share (down from kr0.086 profit in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Karolinska Development Earnings Insights
Looking ahead, revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 40% growth forecast for the Pharmaceuticals industry in Sweden.
Performance of the Swedish Pharmaceuticals industry.
The company's shares are down 2.6% from a week ago.
Risk Analysis
You should learn about the 3 warning signs we've spotted with Karolinska Development (including 2 which are significant).
Valuation is complex, but we're here to simplify it.
Discover if Karolinska Development might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:KDEV
Karolinska Development
A venture capital firm specializing in investments in growth capital, seed stage, and early stage companies.